Section Arrow
Quote
PHIO.NASDAQ
- Phio Pharmaceuticals Corp
Quotes are at least 15-min delayed:2025/03/28 08:23 EDT
Last
 1.31
+0.0095 (+0.73%)
Day High 
1.33 
Prev. Close
1.3005 
1-M High
1.52 
Volume 
32.04K 
Bid
1.27
Ask
1.32
Day Low
1.3 
Open
1.32 
1-M Low
1.2201 
Market Cap 
6.21M 
Currency USD 
P/E 0.01 
%Yield -- 
10-SMA 1.32 
20-SMA 1.34 
50-SMA 1.79 
52-W High 9.79 
52-W Low 1.2201 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-9.75/3.76
Enterprise Value
6.21M
Balance Sheet
Book Value Per Share
1.04
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
15.00K
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
OCEAOcean Biomedical0.078-0.0057-6.81%-- 
DRMADermata Therapeutics Inc.1.42+0.07+5.19%-- 
ONCOOnconetix Inc0.1077+0.0017+1.60%-- 
RGLSRegulus Therapeutics1.5+0.21+16.28%-- 
NKTXNkarta1.97+0.6+43.80%-- 
Quotes are at least 15-min delayed：2025/03/28 08:23 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.